A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin

This is a single-arm, open-label, decentralized (fully remote) clinical trial evaluating the tolerability and self-perceived skin effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in 35 adults aged 18-65 with self-reported eczema-prone skin. Participants will use the body wash once daily in place of their usual cleanser, followed by the Skin Recovery Cream, for 4 consecutive weeks.

Study Overview

• Status: Active, not recruiting
• Conditions: Eczema; Atopic Dermatitis; Eczema-Prone Skin
• Intervention / Treatment: Dietary supplement: Rejuvaskin Eczema Body Wash

• Study Type: Interventional
• Enrollment (Estimated): 35
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Nevada
    • Las Vegas, Nevada, United States, 89118
      • Citruslabs

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adult women or men aged 18-65 years.
• Self-reported symptoms of eczema or eczema-prone skin (e.g., dryness, roughness, itching, irritation on the body).
• Visible signs of eczema such as dryness, roughness, or irritation on at least one part of the body at the time of enrollment.
• Willing to use Rejuvaskin Eczema Body Wash once daily as their primary body cleanser for 4 consecutive weeks.
• Willing to use Rejuvaskin Skin Recovery Cream once daily after using the - Rejuvaskin body cleanser for 4 consecutive weeks.
• Willing to maintain their current diet, skincare routine (aside from substitution of body wash and skin cream), and lifestyle habits for the study duration.
• Willing and able to take standardized photographs of an affected body area at Baseline and Week 4 using a personal smartphone.
• Able to read, understand, and complete questionnaires in English.
• Resides in the United States with a valid shipping address.
• Willing to provide informed consent and comply with all study procedures

Exclusion Criteria:

• Known allergy or sensitivity to any ingredient in the study product.
• Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
• Active, severe skin condition on the body requiring prescription topical or systemic treatment (e.g., active severe atopic dermatitis flare under medical care, active infection at intended application sites).
• Currently using prescription topical corticosteroids, calcineurin inhibitors, or other prescription topical eczema treatments on the body, or initiation of such treatment planned during the study.
• Currently participating in another clinical or skincare research study, or planning to enroll during this study's duration. (

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Rejuvaskin Eczema Body Wash Arm	Dietary supplement: Rejuvaskin Eczema Body Wash; Participants use Rejuvaskin Eczema Body Wash once daily during a shower or bath in place of their usual body cleanser, followed by application of Rejuvaskin Skin Recovery Cream, for 4 consecutive weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from Baseline in Self-Reported Skin Dryness	Mean change in self-reported dryness measured via a structured self-report questionnaire administered through the Citruslabs platform	Baseline to Week 4
Change from Baseline in Self-Reported Skin Roughness	Mean change in self-reported roughness measured via a structured self-report questionnaire administered through the Citruslabs platform	Baseline to Week 4
Change from Baseline in Self-Reported Skin Itch	Mean change in self-reported itch measured via a structured self-report questionnaire administered through the Citruslabs platform	Baseline to Week 4
Change from Baseline in Self-Reported Skin Irritation	Mean change in self-reported irritation measured via a structured self-report questionnaire administered through the Citruslabs platform	Baseline to Week 4
Change from Baseline in Self-Reported Skin Discomfort	Mean change in self-reported discomfort measured via a structured self-report questionnaire administered through the Citruslabs platform	Baseline to Week 4

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from Baseline in Self-Reported Skin Hydration	Mean change in self-reported skin hydration measured via a 0-10 Numeric Rating Scale (NRS) self-report questionnaire	Baseline to Week 4
Change from Baseline in Self-Reported Skin Comfort	Mean change in self-reported skin hydration measured via a 0-10 Numeric Rating Scale (NRS) self-report questionnaire	Baseline to Week 4
Expert Dermatologist-Graded Change in Erythema	Independent expert dermatologist grading of change in erythema from standardized photographs of a designated affected body area	Baseline and Week 4
Expert Dermatologist-Graded Change in Scaling	Independent expert dermatologist grading of change in scaling from standardized photographs of a designated affected body area	Baseline and Week 4

Collaborators and Investigators

• Sponsor: Rejuvaskin
• Collaborators: Citruslabs

Study record dates

Study Major Dates

• Study Start (Actual): July 6, 2026
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): August 1, 2026

Study Registration Dates

• First Submitted: July 7, 2026
• First Submitted That Met QC Criteria: July 7, 2026
• First Posted (Actual): July 14, 2026

Study Record Updates

• Last Update Posted (Actual): July 14, 2026
• Last Update Submitted That Met QC Criteria: July 7, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Genetic Diseases, Inborn; Immune System Diseases; Hypersensitivity, Immediate; Hypersensitivity; Skin Diseases; Skin Diseases, Genetic; Skin Diseases, Eczematous; Dermatitis; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases; Dermatitis, Atopic; Eczema
• Other Study ID Numbers: REJUV-40748

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No